CagriSema

News

Lilly points to long-lasting weight loss with orforglipron

Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.

News

ADA: Novo continues effort to rehabilitate CagriSema

Novo Nordisk's phase 3 data for CagriSema at ADA raises questions about how weight loss data in obesity trials are interpreted.

News

Novo Nordisk's CagriSema data disappoints investors again

Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.

News

Martin Holst Lange, Novo Nordisk's head of development

Novo charts course ahead for CagriSema after lacklustre data

After its first phase 3 trial of obesity hope CagriSema left investors dissatisfied, Novo Nordisk has a plan to get the programme back on track.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

News

Novo Nordisk sheds billions in value on obesity data

Novo Nordisk data on obesity candidate CagriSema falls short of expectations, wiping around $94 billion off its market valuation.

Lilly points to long-lasting weight loss with orforglipron

ADA: Novo continues effort to rehabilitate CagriSema

Novo Nordisk's CagriSema data disappoints investors again

Novo charts course ahead for CagriSema after lacklustre data

11 blockbuster drugs to look out for in 2025

Novo Nordisk sheds billions in value on obesity data

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

CagriSema

Editor's Picks